Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT)

Response to Restriction Requirement

Dated: May 7, 2008

Page 22 of 25

REMARKS

Upon entry of this amendment, Claims 1-13, 21 and 25-29 will be pending in the

present application. Claims 14-20, 22-24 and 30-45 have been cancelled. Amended claims 5, 6, 8, and 13 correct minor editorial errors or provide for more customary claim language. Amended claims 1, 21, 25, 27 and 28, correct minor editorial errors, provide for more customary claim language and/or more clearly define the present invention that the Applicants deem as theirs. Support for amended claims 1 and 21 can be found at, e.g., original claim 1. Support for amended claim 25 can be found at, e.g., original claim 1 and paragraph [0160] of the

specification, while amended claim 27 finds support at, e.g., original claim 1 and paragraph

[0201] of the specification. Amended claim 28 finds support at, e.g., original claim 28. No new

[0201] of the specification. Timended claim 20 finds support at, e.g., original claim 20. 140 new

matter has been added. Applicants make these amendments without prejudice and reserve the

right to pursue any deleted and/or cancelled subject matter in one or more future applications.

The Office has required restriction among twenty-four (24) groups of inventions because allegedly the groups of inventions are not so linked as to form a single inventive concept under PCT Rule 13.1. The alleged twenty-four (24) groups of inventions are:

Group I, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXIV and W is O.

Group II, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXIV and W is S.

Group III, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXV and W is O.

Group IV, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXV and W is S.

Group V, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXVI and W is O.

Group VI, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXVI and W is S.

Group VII, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXVII.

Group VIII, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXVIII.

Group IX, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXXXI and V is N.

Group X, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXXXI and V is C or CH.

Group XI, claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXXXII and T is N or NH.

Group XII claims 1-29 and 37-38 (all in part), are drawn to compounds and compositions of Formula I where Y is formula XXXXII and T is O.

Group XIII, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXIV and W is O.

Group XIV, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXIV and W is S.

Group XV, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXV and W is O.

Group XVI, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXV and W is S.

Group XVII, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXVI and W is O.

Group XVIII, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXVI and W is S.

Group XIX, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXVII.

Page 24 of 25

Group XX, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXVIII.

Group XXI, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXXXI and V is N.

Group XXII, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXXXI and V is C or CH.

Group XXIII, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXXXII and T is N or NH.

Group XXIV, claims 30-36 and 39-45 (all in part), are drawn to methods of use of compounds and compositions of Formula I where Y is formula XXXXII and T is O.

See pages 2-4 of the Office Action. The Office further requires an election of species. See pages 4-5 of the Office Action.

Without conceding the correctness of the Office's position and solely to advance prosecution of the present application, Applicants elect, without traverse, Group X, claims 1-29 and 37-38 (all in part), drawn to compounds and compositions of Formula I where Y is formula XXXXI and V is C or CH, and the species compound:

3,3-dimethyl-N-{2-methyl-4-[(6-trifluoromethylpyridin-3-ylmethyl)-amino]phenyl}-butyramide

(i.e., Example 7e of the specification). Pending claims that are readable on the elected species are claims 1-3, 6, 9, 11, 12, 21, 25, 28 and 29. Applicants note that claims 37-38 of the elected Group X have been canceled since the claims do not further narrow claim 1 of this group.

The Commissioner is hereby authorized to charge any fee or underpayment thereof, or credit any overpayment, to deposit account no. 503201.

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT)

Response to Restriction Requirement

Dated: May 7, 2008 Page 25 of 25

Early reconsideration and allowance is respectfully requested. The Office is invited to contact the undersigned if an interview, telephonic or personal, would facilitate allowance of the claims.

Respectfully submitted,

/Margaret M. Buck/

Margaret M. Buck, Esq. Registration No. 54,010

Lundbeck Research USA, Inc. 215 College Road Paramus, New Jersey 07652 (201) 261-1331 Ext. 790